Today, the reporter noticed on the official website of the US House of Representatives that in the NDAA bill (H.R. 8070 "2025 Fiscal Year Military Quality of Life Improvement and Defense Authorization Act") list being promoted by the House of Representatives, the House of Representatives version of the "Biosecurity Act" (H.R. 8333) is in the "Submitted" state. Jia Kai, a partner at Shanghai Yuandawinston Law Firm who is familiar with the legislative operations of the US Congress, told reporters this means that the bill is attempting to enter the NDAA 2025 House of Representatives version, but the bill submission (Submitted) has not been updated to a proposed discussion deliberation amendment (i.e. Made in Order status), so it should indeed not be included in the NDAA 2025 revision considerations. However, the final situation still needs to pay attention to the official version of the NDAA bill. This matter is independent of the separate legislative process of the "Biosecurity Act" in both houses of the US Congress. (Financial Associated Press)
涉药明系法案在美众议院版NDAA清单中“已提交” 业内判断尚未被纳入NDAA修订考量范畴
The drug-related Ming series bill has been "submitted" in the version of NDAA bill in the US House of Representatives, and it is judged that it has not yet been included in the NDAA revision consideration category within the industry.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.